Design and Bottom-up Production of an Aerosolizable Cannabidiol Nanosuspension
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c01095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Luca Casula und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life and Environmental Sciences, University of Cagliari, 09042 Monserrato, CA,Italy. Hauptthemen laut MEDLINE: Cannabidiol, Nanoparticles, Suspensions, Aerosols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Fondazione di Sardegna, University of Cagliari.
Abstract (Originalsprache)
Cannabidiol (CBD), a small nonpsychoactive molecule derived from Cannabis sativa, exerts a variety of therapeutic actions, such as anti-inflammatory, antioxidant, and antibacterial. Epidiolex is the only FDA-approved medicine containing pure CBD as an oral solution for seizure-controlling therapy. Nevertheless, the oral bioavailability of CBD is challenging due to its physical-chemical properties such as low solubility in water and high first-pass metabolism. By contrast, inhaled CBD has shown faster absorption and higher plasma concentration. Nanosuspensions represent an optimal strategy to obtain an effective aerosolizable formulation of poorly soluble drugs. In this study, a CBD nanosuspension was produced using a bottom-up technique, namely, a solvent/antisolvent nanoprecipitation. The obtained system was thoroughly characterized in terms of dimensions and ζ potential, nanocrystal morphology, and solid-state properties. The formulation was composed of homogeneously dispersed nanocrystals of approximately 88 nm, with a faster dissolution profile compared with the raw drug and the coarse suspension. The nebulization tests carried out using a Next Generation Impactor (NGI, Apparatus E Ph. Eu) highlighted optimal aerodynamic properties with high values of fine particle fraction and MMAD < 5 μm. Finally, the safety of the nanomedicine was assessed on human pulmonary cells demonstrating excellent biocompatibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life and Environmental Sciences, University of Cagliari, 09042 Monserrato, CA,Italy.
- Istituto di Scienze delle Produzioni Alimentari (ISPA)─CNR, Sez. di Sassari, 07040Baldinca, Italy.
- Department of Pharmaceutical Sciences, (DISFARM), University of Milan, 20133 Milano, Italy.
ORCID-Profile: Michele Schlich, Eleonora Lai, Francesco Lai, Elena Pini
Förderung
- Fondazione di Sardegna
- University of Cagliari
Zitieren
APA
Casula, L., Schlich, M., Cardia, M. C., Lai, E., Marceddu, S., Pireddu, R., Valenti, D., Sinico, C., Lai, F., & Pini, E. (2025). Design and Bottom-up Production of an Aerosolizable Cannabidiol Nanosuspension. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01095
Vancouver
Casula L, Schlich M, Cardia MC, Lai E, Marceddu S, Pireddu R, et al. Design and Bottom-up Production of an Aerosolizable Cannabidiol Nanosuspension. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01095
BibTeX
@article{Casula2025,
author = {Casula, Luca and Schlich, Michele and Cardia, Maria Cristina and Lai, Eleonora and Marceddu, Salvatore and Pireddu, Rosa and Valenti, Donatella and Sinico, Chiara and Lai, Francesco and Pini, Elena},
title = {Design and Bottom-up Production of an Aerosolizable Cannabidiol Nanosuspension},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c01095}
}
EUVIMED